Physician profile
Bridgette Coats
NPI 1508370255
$1,943.31
in general payments reported to CMS, 2019-2025
23 companies · $399 in 2025
The $399 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $165 · 2022: $431 · 2023: $631 · 2024: $318 · 2025: $399.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $763 · Consulting Fee: $580 · Education: $4.64.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $762.62 |
| Consulting Fee | $580.00 |
| Education | $4.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $580.00 | 2023 | |
| Pharmacyclics LLC, An Abbvie Company | $262.82 | 2022 | |
| Glaxosmithkline, LLC. | $129.05 | 2024 | Blenrep, Ojjaara |
| E.R. Squibb & Sons, L.L.C. | $125.00 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $118.89 | 2021-2025 | Imfinzi |
| Abbvie INC. | $104.43 | 2025 | |
| Celgene Corporation | $81.02 | 2022-2024 | Reblozyl |
| Rigel Pharmaceuticals, INC. | $70.98 | 2021 | |
| Pfizer INC. | $59.83 | 2023-2025 | |
| Sanofi-Aventis U.S. LLC | $48.81 | 2024-2025 | |
| Gilead Sciences, INC. | $47.62 | 2022-2025 | Trodelvy |
| Stemline Therapeutics INC. | $42.36 | 2025 | Elzonris |
| Iovance Biotherapeutics, INC. | $40.85 | 2025 | Amtagvi |
| Takeda Pharmaceuticals U.S.A., INC. | $36.33 | 2024-2025 | Livtencity |
| Janssen Biotech, INC. | $34.10 | 2024 | Talvey, Tecvayli |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $29.89 | 2025 | Vyloy |
| Ipsen Biopharmaceuticals, INC | $25.29 | 2025 | Tazverik |
| Sobi, INC | $23.42 | 2024 | |
| Legend Biotech USA INC. | $22.55 | 2024 | |
| Syndax Pharmaceuticals, INC. | $21.92 | 2025 | Revuforj |
| Mirati Therapeutics, INC. | $19.41 | 2024 | Krazati |
| Genentech USA, INC. | $14.10 | 2024 | Venclexta |
| Janssen Pharmaceuticals, INC | $4.64 | 2023 | Xarelto |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bridgette Coats listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.